Factors affecting relative dose intensity in patients with Hodgkin lymphoma (HL) receiving doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) without granulocyte-colony stimulating factor (G-CSF) support

被引：0
|
作者：
Kirui, L. C. [1 ]
Cwynarski, K. [1 ]
McNamara, C. [1 ]
机构：
[1] Royal Free Hosp, Dept Haematol, London NW3 2QG, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 157卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
135
引用
收藏
页码：53 / 53
页数：1
相关论文
共 50 条
  • [21] Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF)
    Bobey, N
    Woodman, RC
    CLINICAL AND INVESTIGATIVE MEDICINE, 1998, 21 (02): : 63 - 70
  • [22] Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: Comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy
    Takemoto, Y
    Wada, H
    Takatsuka, H
    Okamoto, T
    Kakishita, E
    DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, 2000, 26 (01) : 1 - 5
  • [23] A randomised study comparing granulocyte-colony stimulating factor (G-CSF) with G-CSF plus thymostimulin in the treatment of haematological toxicity in patients with advanced breast cancer after high dose mitoxantrone therapy
    Sanchiz, F
    Milla, A
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (01) : 52 - 56
  • [24] Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor
    Merdin, Alparslan
    Cakar, Merih Kizil
    Dal, Mehmet Sinan
    Mert, Duygu
    Yildiz, Jale
    Basci, Semih
    Bakirtas, Mehmet
    Darcin, Tahir
    Sahin, Derya
    Ulu, Bahar Uncu
    Yigenoglu, Tugce Nur
    Batgi, Hikmetullah
    Tetik, Aysegul
    Iskender, Dicle
    Altuntas, Fevzi
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (04) : 929 - 932
  • [25] Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy
    Donnelly, GB
    Glassman, J
    Long, C
    Torres, P
    Straus, DJ
    O'Brien, JP
    Bertino, J
    Moskowitz, CH
    Zelenetz, AD
    Portlock, CS
    LEUKEMIA & LYMPHOMA, 2000, 39 (1-2) : 67 - 75
  • [26] THE ROLE GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) IN MAINTAINING CYCLE SCHEDULE AND DOSE INTENSITY DURING CONVENTIONAL-DOSE CHEMOTHERAPY WITH CHOP AND CVP REGIMENS IN NON-HODGKIN-LYMPHOMA (NHL)
    ZAJA, F
    SILVESTRI, F
    VELISIG, M
    VIRGOLINI, L
    GEROMIN, A
    BARILLARI, G
    FANIN, R
    BACCARANI, M
    EXPERIMENTAL HEMATOLOGY, 1994, 22 (08) : 706 - 706
  • [27] Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma
    Niitsu, N
    Umeda, M
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1996, 56 (03) : 163 - 167
  • [28] Granulocyte-Colony Stimulating Factor Use in Young Fit CLL Patients Receiving Fludarabine-Cyclophosphamide-Rituximab Frontline: Impact on Outcomes, Relative Dose Intensity and Toxicities
    Bouvet, Emmanuelle
    Oberic, Lucie
    Recher, Christian
    Huguet, Francoise
    Carles, Xavier
    Laurent, Guy
    Ysebaert, Loic
    BLOOD, 2011, 118 (21) : 785 - 785
  • [29] Didanosine (ddI) ameliorates neutropenia and thrombocytopenia in patients with HIV-associated non-Hodgkin's lymphoma (NHL) treated with infusional cyclophosphamide (C), doxorubicin (D), and etoposide (E) plus granulocyte-colony stimulating factor (G-CSF).
    Sparano, JA
    Wiernik, PH
    Hu, X
    Dutcher, JP
    Sarta, C
    Henry, D
    Mason, B
    BLOOD, 1995, 86 (10) : 3724 - 3724
  • [30] A phase I study of dose-intensified promace-cytabom with prophylactic granulocyte colony stimulating factor (G-CSF) for patients (PTS) with non-Hodgkin's lymphoma (NHL).
    Witzig, TE
    Camoriano, JK
    Schroeder, G
    Kurtin, PJ
    Habermann, TM
    BLOOD, 1996, 88 (10) : 2263 - 2263
12345